REPH

Recro Pharma, Inc. [REPH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

REPH Stock Summary

In the News

07:33 28 Mar 2024 REPH

Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript

Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript

04:05 28 Mar 2024 REPH

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern

07:00 28 Mar 2024 REPH

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.

10:36 28 Mar 2024 REPH

Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

02:20 28 Mar 2024 REPH

Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript

Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript

03:07 28 Mar 2024 REPH

Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic

Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).  The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.

07:00 28 Mar 2024 REPH

Recro Reports Inducement Grants For New Staff

Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego

10:09 28 Mar 2024 REPH

Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

01:44 28 Mar 2024 REPH

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07:00 28 Mar 2024 REPH

Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth

REPH Financial details

Company Rating
Buy
Market Cap
177.42M
Income
-21.66M
Revenue
91.2M
Book val./share
0
Cash/share
0
Dividend
-
Dividend %
-
Employees
185
Optionable
No
Shortable
Yes
Earnings
04 May 2022
P/E
-6500.08
Forward P/E
-
PEG
939.16
P/S
1.96
P/B
3166.2
P/C
-
P/FCF
-21.03
Quick Ratio
1.1
Current Ratio
2.45
Debt / Equity
0.26
LT Debt / Equity
0.07
-
-
EPS (TTM)
-0.16
EPS next Y
-
EPS next Q
-
EPS this Y
-34.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-38.61%
Revenue last 5Y
3.13%
Revenue Q/Q
8.22%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-18%
ROE
-58%
ROC
-0.3%
Gross Margin
22%
Oper. Margin
-43%
Profit Margin
-30%
Payout
-
Shs Outstand
84.89M
Shs Float
69.97M
-
-
-
-
Target Price
-
52W Range
2.0001-2.14
52W High
-
52W Low
-
RSI
-
Rel Volume
1.07
Avg Volume
128.49K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.11537
-
-
Volatility
0.61%, 0.61%
Prev Close
-
Price
-
Change
-

REPH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
3.784.22.81.471.56
Net income per share
-3.9-0.79-1.16-0.52-0.34
Operating cash flow per share
-2.11-1.080.340.21-0.06
Free cash flow per share
-2.63-1.430.020.11-0.21
Cash per share
1.880.8110.490.26
Book value per share
-0.95-0.28-0.590.821.03
Tangible book value per share
-2.84-0.61-0.81-0.060.27
Share holders equity per share
-0.95-0.28-0.590.821.03
Interest debt per share
3.575.525.422.31-0.01
Market cap
145.3M432.75M67.67M87.92M120.96M
Enterprise value
171.03M524.44M153.48M166.23M119.21M
P/E ratio
-1.82-23.23-2.46-3.32-6.08
Price to sales ratio
1.884.361.021.171.34
POCF ratio
-3.37-16.978.398.1-33.2
PFCF ratio
-2.7-12.79145.8415.79-10.08
P/B Ratio
-7.45-64.47-4.82.092.02
PTB ratio
-7.45-64.47-4.82.092.02
EV to sales
2.215.292.312.211.32
Enterprise value over EBITDA
-3.7454.77748.6914.67427.28
EV to operating cash flow
-3.97-20.5719.0315.31-32.71
EV to free cash flow
-3.18-15.5330.7829.85-9.94
Earnings yield
-0.55-0.04-0.41-0.3-0.16
Free cash flow yield
-0.37-0.080.010.06-0.1
Debt to equity
-3.29-16.46-7.772.460.22
Debt to assets
0.4111.060.650.08
Net debt to EBITDA
-0.569.57418.596.91-6.29
Current ratio
2.459.286.933.242.44
Interest coverage
-6.171.19-0.440.252.34
Income quality
0.541.37-0.29-0.950.18
Dividend Yield
0000.370
Payout ratio
000-1.210
Sales general and administrative to revenue
0.480000
Research and developement to revenue
0.520000
Intangibles to total assets
0.250.070.050.280.28
Capex to operating cash flow
0.250.33-0.94-0.492.29
Capex to revenue
-0.14-0.08-0.11-0.07-0.09
Capex to depreciation
-1.35-0.99-0.89-0.7-1
Stock based compensation to revenue
0.090.060.150.090.06
Graham number
9.142.253.933.082.83
ROIC
-1.550.19-0.090.06-0.44
Return on tangible assets
-0.68-0.18-0.28-0.23-0.18
Graham Net
-5.75-3.09-3.19-1.42-1.13
Working capital
42.11M53.68M46.27M39.79M32.78M
Tangible asset value
-58.21M-14.31M-19.12M-2.85M15.85M
Net current asset value
-103.85M-57.01M-63.45M-60.72M-42M
Invested capital
-3.29-16.46-7.772.460.22
Average receivables
13.88M20.65M19.8M18.42M18.21M
Average payables
6.23M2.75M1.4M1.94M1.78M
Average inventory
10.27M12.89M13.34M10.26M9.61M
Days sales outstanding
85.2685.4989.8199.1864.53
Days payables outstanding
38.147.0812.1613.77.98
Days of inventory on hand
90.48107.9178.2958.656.05
Receivables turnover
4.284.274.063.685.66
Payables turnover
9.5751.5530.0126.6445.75
Inventory turnover
4.033.384.666.236.51
ROE
4.092.781.95-0.63-0.33
Capex per share
-0.52-0.35-0.32-0.1-0.14

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.380.42000
Net income per share
-0.12-0.16000
Operating cash flow per share
0.010.03000
Free cash flow per share
-0.03-0.01000
Cash per share
0.20.26000
Book value per share
0.621.03000
Tangible book value per share
-0.160.27000
Share holders equity per share
0.621.03000
Interest debt per share
0.2-0.19000
Market cap
118.43M120.96M177.23B182.52B210.33B
Enterprise value
114.65M119.21M177.24B0210.34B
P/E ratio
-4.31-3.3-9.46K-14.21K-11.45K
Price to sales ratio
5.494.988.23K8.37K8.92K
POCF ratio
250.3960.66-62.12K00
PFCF ratio
-64.51-163.03-28.45K00
P/B Ratio
3.362.023.17K03.61K
PTB ratio
3.362.023.17K03.61K
EV to sales
5.314.918.23K08.92K
Enterprise value over EBITDA
48.15-3.08-68.22K0-119.71K
EV to operating cash flow
242.3859.78-62.12K00
EV to free cash flow
-62.44-160.66-28.45K00
Earnings yield
-0.06-0.08000
Free cash flow yield
-0.02-0.01000
Debt to equity
0.220.220.2400.26
Debt to assets
0.050.080.0900.1
Net debt to EBITDA
-1.590.05-2.740-4.04
Current ratio
3.492.442.4502.3
Interest coverage
0.061.333.150.420.6
Income quality
-0.14-0.220.6100
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.290.280.2900.29
Capex to operating cash flow
-4.88-1.371.1800
Capex to revenue
-0.11-0.11-0.1600
Capex to depreciation
-1.07-1.29-1.6200
Stock based compensation to revenue
0.060.050.0500
Graham number
1.31.92000
ROIC
0.01-0.47-0.090-0.02
Return on tangible assets
-0.06-0.08-0.040-0.04
Graham Net
-1.53-1.13000
Working capital
35.31M32.78M28.31M028.16M
Tangible asset value
-8.99M15.85M12.16M014.77M
Net current asset value
-66.55M-42M-46.12M0-43.49M
Invested capital
0.220.220.2400.26
Average receivables
16.81M16.53M15.59M00
Average payables
2.7M2.26M1.93M00
Average inventory
8.89M9.86M10.94M00
Days sales outstanding
71.359.1363.67056.35
Days payables outstanding
17.147.5711.1709.62
Days of inventory on hand
52.7753.1754.03055.62
Receivables turnover
1.261.521.4101.6
Payables turnover
5.2511.898.0609.35
Inventory turnover
1.711.691.6701.62
ROE
-0.2-0.15-0.080-0.08
Capex per share
-0.04-0.05000

REPH Frequently Asked Questions

What is Recro Pharma, Inc. stock symbol ?

Recro Pharma, Inc. is a US stock , located in Malvern of Pennsylvania and trading under the symbol REPH

What is Recro Pharma, Inc. stock quote today ?

Recro Pharma, Inc. stock price is $- today.

Is Recro Pharma, Inc. stock public?

Yes, Recro Pharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap